Cagrilintide holds real promise as a peptide therapy for weight management, but like any medical treatment, it comes with side effects that deserve your full attention
Overall, it is unlikely that there exists an intracellular signalling pathway that is both highly specific for nausea and also accessible to exclusive modulation by biased GLP1 agonists
Your body's GLP-1 receptors remain engaged by the medication already in circulation, and the short gap does not cause rebound appetite, blood sugar spikes, or other complications
Recognizing her expertise in maintaining a healthy lifestyle, Williams sought additional support and turned to Ro, a direct-to-patient healthcare company, to begin a GLP-1 program
208 MichaowskaJMiller-KasprzakEBogdaskiP
doi: 10.1016/j.rmed.2016.06.015